Search results
1 kwi 2019 · Although a rare disease, aplastic anemia should be distinguished from other cases of pancytopenia, and patients should receive the best treatment available based on their age, and the existence of a matched sibling donor.
- Diagnosis and Treatment of Aplastic Anemia - PMC - National Center for ...
Once the diagnostic evaluation is complete, treatment is...
- Aplastic Anemia - StatPearls - NCBI Bookshelf
Over the past 3 decades, the prognosis for patients with...
- Diagnosis and Treatment of Aplastic Anemia - PMC - National Center for ...
11 lis 2017 · Once the diagnostic evaluation is complete, treatment is guided by the AA severity, established by the Camitta criteria (Figure 1) [16, 17]. For younger patients with severe aplastic anemia (SAA) or very severe aplastic anemia (VSAA), a transplant evaluation should be rapidly initiated.
17 lip 2023 · Over the past 3 decades, the prognosis for patients with aplastic anemia has markedly improved because of better treatment and supportive measures. Depending on the cause, with treatment 10-year survival of 65-75 have been reported with immunosuppressive and hematopoietic cell transplantation.
22 cze 2021 · Minor population of CD55−CD59− blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia.
24 paź 2018 · Once a uniformly fatal disease, aplastic anemia is now curable with allogeneic transplantation in 80% of children and 40% of adults, and immunosuppression with or without eltrombopag can induce...
1 sty 2006 · Judith Marsh. Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 78–85. https://doi.org/10.1182/asheducation-2006.1.78. Split-Screen. Share. Tools. Abstract. The management of adults presenting with aplastic anemia (AA) requires careful exclusion of other causes of bone marrow failure.
10 gru 2011 · For those without a sibling donor, the high response and overall survival rates of combined immunosuppressive therapy (IST) have proven robust. Nonetheless, incomplete response, relapse, and progression to myelodysplasia/leukemia have more clearly emerged as significant long-term issues.
